33.31
price up icon0.60%   0.20
pre-market  Pre-mercato:  32.81   -0.50   -1.50%
loading
Precedente Chiudi:
$33.11
Aprire:
$32.98
Volume 24 ore:
737.02K
Relative Volume:
0.77
Capitalizzazione di mercato:
$2.93B
Reddito:
$4.72M
Utile/perdita netta:
$-277.91M
Rapporto P/E:
-8.9303
EPS:
-3.73
Flusso di cassa netto:
$-203.56M
1 W Prestazione:
+6.52%
1M Prestazione:
-4.09%
6M Prestazione:
-40.79%
1 anno Prestazione:
-24.30%
Intervallo 1D:
Value
$32.20
$33.59
Intervallo di 1 settimana:
Value
$31.68
$33.59
Portata 52W:
Value
$24.10
$62.53

Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile

Name
Nome
Crinetics Pharmaceuticals Inc
Name
Telefono
858-450-6464
Name
Indirizzo
10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA
Name
Dipendente
437
Name
Cinguettio
@Crinetics
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
CRNX's Discussions on Twitter

Confronta CRNX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CRNX
Crinetics Pharmaceuticals Inc
33.31 2.93B 4.72M -277.91M -203.56M -3.73
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
503.50 126.09B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
568.91 64.01B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
629.51 36.63B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
257.19 30.64B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.77 27.24B 3.81B -644.79M -669.77M -6.24

Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-25 Iniziato Stifel Buy
2025-02-11 Iniziato TD Cowen Buy
2025-02-04 Iniziato Wolfe Research Peer Perform
2025-01-22 Aggiornamento Jefferies Hold → Buy
2024-03-06 Iniziato Citigroup Buy
2024-01-16 Iniziato Morgan Stanley Overweight
2023-12-21 Iniziato Jefferies Hold
2023-11-20 Ripresa JP Morgan Overweight
2023-10-24 Ripresa Cantor Fitzgerald Overweight
2023-08-31 Iniziato Oppenheimer Outperform
2023-04-24 Iniziato Piper Sandler Overweight
2023-03-30 Iniziato Robert W. Baird Outperform
2021-11-30 Iniziato JMP Securities Mkt Outperform
2021-11-23 Iniziato Evercore ISI Outperform
2021-06-18 Aggiornamento JP Morgan Neutral → Overweight
2019-12-23 Iniziato ROTH Capital Buy
2019-02-14 Iniziato H.C. Wainwright Buy
2018-08-13 Iniziato JP Morgan Neutral
2018-08-13 Iniziato Leerink Partners Outperform
2018-08-13 Iniziato Piper Jaffray Overweight
Mostra tutto

Crinetics Pharmaceuticals Inc Borsa (CRNX) Ultime notizie

pulisher
Apr 28, 2025

LPL Financial LLC Acquires 1,162 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Apr 28, 2025
pulisher
Apr 25, 2025

Market Watch Highlights: Crinetics Pharmaceuticals Inc (CRNX) Ends on an Upturn Note at 33.39 - DWinneX

Apr 25, 2025
pulisher
Apr 25, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock Holdings Boosted by Envestnet Asset Management Inc. - Defense World

Apr 25, 2025
pulisher
Apr 23, 2025

Are Crinetics Pharmaceuticals Inc (CRNX) shares a good deal now? - uspostnews.com

Apr 23, 2025
pulisher
Apr 22, 2025

CRNX stock touches 52-week low at $35.47 amid market shifts - MSN

Apr 22, 2025
pulisher
Apr 22, 2025

Crinetics Pharmaceuticals patents new SSTR3 agonists - BioWorld MedTech

Apr 22, 2025
pulisher
Apr 21, 2025

Wells Fargo & Company MN Increases Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Apr 21, 2025
pulisher
Apr 21, 2025

Invesco Ltd. Acquires 42,954 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Apr 21, 2025
pulisher
Apr 20, 2025

Russell Investments Group Ltd. Sells 43,501 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Apr 20, 2025
pulisher
Apr 17, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Affinity Asset Advisors LLC - MarketBeat

Apr 17, 2025
pulisher
Apr 14, 2025

Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Unloaded Rep. Josh Gottheimer - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by Alliancebernstein L.P. - Defense World

Apr 13, 2025
pulisher
Apr 13, 2025

JPMorgan Chase & Co. Has $13.78 Million Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Apr 13, 2025
pulisher
Apr 13, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 | CRNX Stock News - GuruFocus

Apr 12, 2025
pulisher
Apr 11, 2025

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 - The Manila Times

Apr 11, 2025
pulisher
Apr 11, 2025

Key Investor Alert: Crinetics Sets Date for Crucial Q1 2025 Financial Results - Stock Titan

Apr 11, 2025
pulisher
Apr 10, 2025

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com

Apr 10, 2025
pulisher
Apr 10, 2025

Acromegaly Pipeline 2025: Detailed Clinical Trials - openPR.com

Apr 10, 2025
pulisher
Apr 10, 2025

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 10, 2025
pulisher
Apr 07, 2025

Stock Surge: Crinetics Pharmaceuticals Inc (CRNX) Closes at 26.89, Marking a -6.86 Increase/Decrease - DWinneX

Apr 07, 2025
pulisher
Apr 05, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Sei Investments Co. - Defense World

Apr 05, 2025
pulisher
Apr 02, 2025

Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA - Seeking Alpha

Apr 02, 2025
pulisher
Mar 31, 2025

CRNX stock touches 52-week low at $31.81 amid market challenges - Investing.com

Mar 31, 2025
pulisher
Mar 27, 2025

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation Of Marketing Authorization Application (MAA) And Orphan Drug Designation (ODD) For Paltusotine In Acromegaly - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

Breakthrough: First Oral Acromegaly Drug Hits Major EU Milestone with Dual Regulatory Wins - Stock Titan

Mar 27, 2025
pulisher
Mar 26, 2025

Crinetics Pharmaceuticals (NASDAQ:CRNX) Now Covered by Stifel Nicolaus - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology - Benzinga

Mar 25, 2025
pulisher
Mar 25, 2025

This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Mar 25, 2025
pulisher
Mar 25, 2025

Stifel Initiates Coverage of Crinetics Pharmaceuticals (CRNX) with Buy Recommendation - Nasdaq

Mar 25, 2025
pulisher
Mar 25, 2025

Stifel Initiates Crinetics Pharmaceuticals at Buy With $60 Price Target - Marketscreener.com

Mar 25, 2025
pulisher
Mar 25, 2025

Taking a Closer Look At Crinetics Pharmaceuticals Inc (CRNX) Following Its Recent Trade - knoxdaily.com

Mar 25, 2025
pulisher
Mar 24, 2025

Cushing's Syndrome Pipeline 2025: Therapies, MOA Insights, - openPR.com

Mar 24, 2025
pulisher
Mar 24, 2025

(CRNX) Trading Report - news.stocktradersdaily.com

Mar 24, 2025
pulisher
Mar 24, 2025

Connor Clark & Lunn Investment Management Ltd. Sells 13,735 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

Proficio Capital Partners LLC Purchases Shares of 14,674 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Mar 23, 2025
pulisher
Mar 22, 2025

Crinetics Pharmaceuticals COO Jeff Knight sells $244,963 in stock By Investing.com - Investing.com Australia

Mar 22, 2025
pulisher
Mar 22, 2025

Zurcher Kantonalbank Zurich Cantonalbank Purchases 2,970 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - The AM Reporter

Mar 22, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals’ chief med and dev officer sells $86,020 in stock - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Stock: Executives Sell Shares Amid Analyst Optimism - sharewise.com

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals’ chief med and dev officer sells $86,020 in stock By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals CEO Richard Struthers sells shares worth $592,016 By Investing.com - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals COO Jeff Knight sells $244,963 in stock - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals chief scientific officer sells $197,352 in stock By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals CEO Richard Struthers sells shares worth $592,016 - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals chief scientific officer sells $197,352 in stock - Investing.com

Mar 21, 2025
pulisher
Mar 19, 2025

CRNX News Today | Why did Crinetics Pharmaceuticals stock go down today? - MarketBeat

Mar 19, 2025
pulisher
Mar 19, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Mar 19, 2025
pulisher
Mar 16, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Charles Schwab Investment Management Inc. - Defense World

Mar 16, 2025

Crinetics Pharmaceuticals Inc Azioni (CRNX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.79
price up icon 0.78%
$71.40
price up icon 2.20%
$32.71
price up icon 0.52%
$23.62
price down icon 2.03%
$104.00
price up icon 0.00%
biotechnology ONC
$249.77
price up icon 0.12%
Capitalizzazione:     |  Volume (24 ore):